Discover RNA token, likely connected to biotech DAOs or decentralized science (DeSci). This feed compiles breakthroughs in genetic data marketplaces and research funding initiatives on‑chain.
Ionis (IONS) stock plunged 20% after eplontersen failed its Phase 3 heart disease trial, while competitors Alnylam and BridgeBio surged on the news. The post Ionis
2026/07/09
Ionis Pharmaceuticals (IONS) stock plunged 20% after eplontersen missed its Phase 3 CARDIO-TTRansform trial endpoint in heart disease patients. The post Ionis Pharmaceuticals
TLDR Ionis shares tumble after eplontersen misses key Phase 3 heart trial goal today IONS sinks in pre-market after ATTR-CM study misses main Phase 3 efficacy goal
Study identifies c-Jun–Irf8–CD36 axis as key driver of fibrotic scarring after spinal cord injury. Targeting CD36 or c-Jun reduces scar formation, improves regeneration
2026/07/02
Annovis Bio (NYSE: ANVS) promotes Dr. Cheng Fang to chief scientific officer as it advances buntanetap toward Phase 3 Alzheimer's data and NDA submission. The post
2026/07/01
Creative Diagnostics launches Hantavirus Research Reagents and Products to support diagnostic assay development and therapeutic research for hantavirus diseases
2026/06/26
KLANG, June 20 — The National Food Security Act is expected to be tabled in Parliament next year, Agriculture and...
2026/06/20
ALOR SETAR, June 19 — A woman who had been reported missing since 2019 after leaving her family home in Johor Bahr...
2026/06/19
Moderna may finally prove that its platform still matters.
2026/06/18
KUALA LUMPUR, June 17 — Airbus has confirmed that AirAsia X’s order for 15 Airbus A330-900 aircraft has been...
2026/06/17